04-775 | Anti-Ha-Ras Antibody, clone MC57, rabbit monoclonal

04-775
100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Click To Print This Page

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, RWBRbCulture SupernatantMonoclonal Antibody
      Description
      Catalogue Number04-775
      Replaces05-775
      DescriptionAnti-Ha-Ras Antibody, clone MC57, rabbit monoclonal
      Alternate Names
      • GTP- and GDP-binding peptide B
      • GTPase HRas
      • Ha-Ras1 proto-oncoprotein
      • Ras family small GTP binding protein H-Ras
      • Transforming protein p21
      • c-has/bas p21 protein
      • c-ras-Ki-2 activated oncogene
      • p19 H-RasIDX protein
      • transformation gene: oncogene HAMSV
      • v-Ha-ras Harvey rat sarcoma viral oncogene homolog
      Background InformationRas proteins are small GTP-binding proteins which, unlike the heterotrimeric G-proteins, contain all GTPase and effector functions within a single polypeptide. At least three isoforms of Ras exist, Ki-Ras, Ha-Ras and N-Ras, with distinct expression patterns but similar signaling activity. Ras is palmitoylated and farnesylated at the carboxy terminus, anchoring it in the membrane. In resting cells, Ras is loaded with GDP, and is activated subsequent to growth factor stimulation of receptors, which recruit Ras Guanine nucleotide Exchange Factors to the plane of the membrane. Proximity of exchange factors to the Ras proteins causes release of GDP, and its replacement by GTP. In its GTP-bound form, Ras binds several proteins, including Raf, RalGDS and PI3 Kinase. Inactivation of Ras occurs by GTP hydrolysis, which is greatly accelerated by RasGAP or NF-1, two known Ras GTPase Activating Proteins. It is possible to assay for Ras activation by incubation of lysates with the Ras-binding domain of Raf-1, which selectively binds to Ras:GTP.
      References
      Product Information
      FormatCulture Supernatant
      Control
      • Included Positive Antigen Control: Catalog # 12-301, non-stimulated A431 lysate. Add 2.5 μL of 2-mercaptoethanol/100 μL of lysate and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced lysate per lane for minigels.
      PresentationCultured supernantant containing 0.05% sodium azide.
      Applications
      ApplicationDetect Ha-Ras using this Anti-Ha-Ras Antibody, clone MC57 validated for use in WB.
      Key Applications
      • Western Blotting
      Biological Information
      ImmunogenGST fusion protein corresponding to full length human Ha-Ras. Clone MC57.
      CloneMC57
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostRabbit
      SpecificityRecognizes Ha-Ras, Mr ~21 kDa. Does not cross react with Cdc42, Rho or Rac1.
      IsotypeIgG
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Species Reactivity NoteHuman. Predicted to cross-react with mouse and rat based on sequence homology.
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus.Mutations in this gene cause Costello syndrome, a disease
      characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.
      Gene Symbol
      • C-BAS/HAS
      • C-H-RAS
      • C-HA-RAS1
      • CTLO
      • H-RASIDX
      • H-Ras-1
      • HAMSV
      • HRAS1
      • Ha-Ras
      • K-RAS
      • N-RAS
      • OTTHUMP00000162769
      • OTTHUMP00000166053
      • OTTHUMP00000166055
      • RASH1
      • c-H-ras
      • p21ras
      UniProt Number
      UniProt SummaryFUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Ref.18 Ref.32
      ENZYME REGULATION: Alternate between an inactive form bound to GDP and an active form bound to GTP. Activated by a guanine nucleotide-exchange factor (GEF) and inactivated by a GTPase-activating protein (GAP).
      SUBUNIT STRUCTURE: In its GTP-bound form interacts with PLCE1. Interacts with TBC1D10C. Interacts with RGL3 By similarity. Forms a signaling complex with RASGRP1 and DGKZ. Interacts with RASSF5.
      SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor; Cytoplasmic side. Golgi apparatus membrane; Lipid-anchor. Note: Shuttles between the plasma membrane and the Golgi apparatus.
      PTM: Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi. S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
      INVOLVEMENT IN DISEASE:Defects in HRAS are the cause of Costello syndrome [MIM:218040]; also known as faciocutaneoskeletal syndrome. Costello syndrome is a rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
      Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
      Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma [MIM:607464]; also known as Hurthle cell thyroid neoplasia. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms. Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors. Defects in HRAS are a cause of bladder cancer. Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
      SEQUENCE SIMILARITIES: Belongs to the small GTPase superfamily. Ras family.
      MASS SPECTROMETRY: Molecular mass is 6.223±2 Da from positions 112 - 166. Determined by ESI. Molecular mass is 6.253±2 Da from positions 112 - 166. Determined by ESI. Includes one nitric oxide molecule.
      Molecular Weight~21 kDa
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceWestern Blot Analysis: A 1:1000 dilution of this antibody detected Ha-Ras in RIPA lysates from A431 cells.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20ºC from date of receipt.
      Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications

      Related Products & Applications

      Product Families

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies